We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Ultra-Absorptive Nanofiber Swabs Could Improve SARS-CoV-2 Test Sensitivity

By LabMedica International staff writers
Posted on 29 Jan 2021
Researchers have developed ultra-absorptive nanofiber swabs that could reduce the number of false-negative tests by improving sample collection and test sensitivity for SARS-CoV-2.

The nanofiber swab was developed by researchers at the University of Nebraska Medical Center (UNMC; Omaha, NE, USA) by using an electrospinning technique. More...
Currently, the most sensitive test for COVID-19 involves using a long swab to collect a specimen from deep inside a patient's nose, and then using a method called reverse transcriptase-polymerase chain reaction (RT-PCR) to detect SARS-CoV-2 RNA. But if the viral load is low, which can occur early in the course of infection, the swab might not pick up enough virus to be detectable. The UNMC researchers wanted to develop a nanofiber swab that could absorb and then release more viruses and other biological specimens, improving the sensitivity of diagnostic tests.

The researchers used an electrospinning technique to make one-cm-long cylinders composed of aligned nanofiber layers, which they coated with a thin layer of gelatin and bonded to plastic swab sticks. In lab tests, the porous nanofiber cylinders absorbed and released more proteins, cells, bacteria, DNA and viruses from liquids and surfaces than the cotton or flocked swabs commonly used for COVID-19 testing. The team made dilutions of SARS-CoV-2 virus, swabbed the liquid samples and tested for viral RNA with RT-PCR. Compared with the two other types of swabs, the nanofiber ones reduced the false-negative rate and detected SARS-CoV-2 at a 10-times lower concentration.

Related Links:
University of Nebraska Medical Center


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Biomarker Algorithm Clarifies Uncertain Alzheimer’s Amyloid Status

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image

GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026

GeneDx (Gaithersburg, MD, USA) is presenting 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montreal, Canada.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.